ABRYSVO is a vaccine to help prevent disease of the lower respiratory tract (lungs) caused by RSV (respiratory syncytial virus). ABRYSVO is given to pregnant individuals (32 through 36 weeks' gestation) to protect their infants from birth through 6 months of age. As with any vaccine, ABRYSVO will not protect 100% of those who receive it. ABRYSVO is not a treatment for RSV infection or its complications.
To help avoid side effects and ensure proper use, talk to your doctor before you receive ABRYSVO. Talk about any health conditions or problems you may have, including if you:
- have ever had a severe allergic reaction or breathing problems after any other vaccine injection or after you were given ABRYSVO in the past.
- have a bleeding problem or bruise easily.
- have an infection with a high fever. If this is the case, then vaccination will be postponed. There is no need to delay vaccination for a minor infection, such as a cold, but talk to your doctor first.
- are feeling nervous about the vaccination process or have ever fainted following any needle injection.
- have a weakened immune system, which may prevent you from getting the full benefit from ABRYSVO.
- are less than 32 weeks pregnant. Pregnant individuals can be given this vaccine in the third trimester (Weeks 32 through 36). ABRYSVO is not recommended in children and adolescents below 18 years of age, except in pregnancy.
Like all vaccines, ABRYSVO can cause side effects, although not everybody gets them. Side effects after receiving ABRYSVO include pain where the injection was given, headache, muscle pain, redness where the injection was given, and swelling where the injection was given. Allergic reactions could also occur. No side effects were reported in infants born to vaccinated mothers. This is not a complete list of side effects. If you experience any side effects not listed here, tell your doctor.
For more information, please consult the Product Monograph or call 1-800-463-6001.
ABRYSVO is a vaccine to help prevent disease of the lower respiratory tract (lungs) caused by RSV (respiratory syncytial virus). ABRYSVO is given to pregnant individuals (from 32 through 36 weeks’ gestation) to protect their infants from birth through 6 months of age, and individuals 60 years of age and older. As with any vaccine, ABRYSVO will not protect 100% of those who receive it. ABRYSVO is not a treatment for RSV infection or its complications. Like all vaccines, ABRYSVO can cause side effects, although not everybody gets them.
For more information, please consult the Product Monograph or call 1-800-463-6001.